volume 270, issue 1-2, P1-8 2004
DOI: 10.1016/j.ijpharm.2003.09.046
View full text
|
|
Share

Abstract: Azithromycin (AZI) follows a two-compartment model pharmacokinetically. The purpose of this study was to evaluate the in vivo performance of a controlled release (CR) formulation of AZI, which would eliminate the risk of high peak plasma concentrations obtained within 2-3 h after peroral administration of immediate release (IR) products. The study was conducted in twelve healthy male human volunteers to compare an experimental NIPER product (CR tablets) with Vicon (IR tablets) at the same dose level as a singl…

expand abstract